LFA
CYTK icon

LGT Financial Advisors’s Cytokinetics CYTK Stock Holding History

LGT Financial Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-583
Closed -$27.4K – 408
2024
Q4 		$27.4K Hold
583
– – 0.06% 240
2024
Q3 		$30.8K Hold
583
– – 0.08% 193
2024
Q2 		$31.6K Hold
583
– – 0.07% 216
2024
Q1 		$40.9K Hold
583
– – 0.05% 249
2023
Q4 		$48.7K Hold
583
– – 0.06% 217
2023
Q3 		$17.2K Buy
+583
New +$19.4K 0.02% 374

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LGT Financial Advisors's CYTK Position: Q1 2025 in Review

LGT Financial Advisors sold out of Cytokinetics (CYTK) in Q1 2025, closing a stake of 583 shares — an estimated $27.4K sold.

LGT Financial Advisors first reported a position in CYTK in Q3 2023 and held it in 6 quarters. The position peaked at $48.7K in Q4 2023. 355 funds tracked by Wall St. Rank hold CYTK as of Q1 2025.

  • LGT Financial Advisors reported no remaining Cytokinetics position as of Q1 2025 after selling out during the quarter.
  • LGT Financial Advisors sold 583 Cytokinetics shares in Q1 2025, an estimated $27.4K.
  • LGT Financial Advisors first reported a position in Cytokinetics in Q3 2023 and held it in 6 quarters.
  • LGT Financial Advisors's Cytokinetics position peaked at $48.7K in Q4 2023.
  • 355 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2025.

Based on LGT Financial Advisors's 13F filing for Q1 2025, filed 8 May 2025.